A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive

NCT05603156 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Ph+ ALL
Bone Marrow Transplant
Minimal Residual Disease

Interventions

DRUG: the usage of Olverembatinib combined with Inotuzumab Ozogamicin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China